• About
    Lymphoid neoplasms encompassing lymphomas and some leukemia like Chronic Lymphocytic Leukaemia (CLL) are the most common type of blood cancer .
    With increasing evidence for the stratification of tumor types with distinct clinical and biological features according to biomarkers, and the progress in targeted therapy, tailored NGS-based workflows empower experts to get high-quality and reproducible data to accelerate their studies. Watch our “SOPHiA DDM™ Community CLL Clonality Solution: The importance of biomarker analysis in CLL” webinar by Dr. Ferran Nadeu, Fundació de Recerca Clínic Barcelona-IDIBAPS, Molecular Pathology of Lymphoid Neoplasms Research Group.

    Disclaimer notice:
    The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
    The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
    SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
    SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
  • Price
  • Language
  • Dial-in available
    (listen only)
    Not available.